Armie Grammer, AMPEL’s co-founder, president, and chief scientific officer of AMPEL BioSolutions, explains the company’s CardioGENE blood test for cardiovascular disease risk.
AMPEL develops a blood test for cardiovascular disease
read more
New Blood Test Can Predict Heart Disease and Guide Prophylactic Treatment
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways, enabling personalized, preventive therapies.
Precision Medicine Blood Test Predicts Heart Disease Before It Occurs
A precision medicine blood test can predict heart disease before it happens and provide decision support for prophylactic therapies.
AMPEL BioSolutions: Precision Medicine Blood Testing Predicts Heart Disease and Therapeutic Intervention
AMPEL BioSolutions announced a precision medicine blood test that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Charlottesville company creates early genetic test to predict heart disease
It’s a breakthrough discovery for the first-time identifying risk factors in inflammation and the immune system that lead to cardiovascular events. Outside the traditional risk factors of smoking, high fat diet and sedentary lifestyle. Cardio Gene could be a game changer
New Test Helps Predict Heart Disease in Lupus Patients
AMPEL BioSolutions has announced that its genetic precision medicine test for lupus patients could predict heart disease and provide decision support for prophylactic therapies.